Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 6/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | HTR7 | P34969 | 4/20 | 0.42 |
| ▸ | HTR1A | P08908 | 2/20 | 0.42 |
| ▸ | NOS3 | P29474 | 1/20 | 0.41 |
| ▸ | NOS1 | P29475 | 1/20 | 0.41 |
| ▸ | NOS2 | P35228 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | LTA4H | P09960 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5756326 | 0.91 | HTR6 (0.46) | HTR6HRH3KCNH2HTR7HTR1A | |
| SCHEMBL5753820 | 0.91 | HTR6 (0.55) | HTR6HRH3HTR7TSHRLTA4H | |
| SCHEMBL4076472 | 0.87 | ALDH1A1 (0.47) | HTR6HRH3KCNH2TSHRLTA4H | |
| SCHEMBL4084560 | 0.81 | RAB9A (0.47) | HTR6HRH3HTR7HTR1ATSHR | |
| SCHEMBL4075300 | 0.80 | HTR7 (0.45) | HTR6HTR7HTR1ATSHR | |
| SCHEMBL4082363 | 0.78 | TSHR (0.44) | HTR6HRH3HTR7NOS3NOS1 | |
| Hydrochloric Acid SCHEMBL5791114 | 0.77 | LTA4H (0.41) | HTR6HRH3HTR7TSHRLTA4H | |
| SCHEMBL6348666 | 0.76 | HTR6 (0.49) | HTR6 | |
| SCHEMBL13708115 | 0.76 | TDP1 (0.52) | HTR6HRH3HTR7NOS3NOS1 | |
| SCHEMBL4082858 | 0.75 | HTR6 (0.45) | HTR6HRH3HTR7HTR1AHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1353904-B9 | 1-ARYL-OR 1-ALKYLSULFONYLBENZAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH CORP (US) | 2006-05-03 | — | — | EP | claimed |
| EP-1353904-B1 | 1-ARYL-OR 1-ALKYLSULFONYLBENZAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH CORP (US) | 2005-12-07 | — | — | EP | claimed |
| US-20040092564-A1 | 1-Aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH | 2004-05-13 | — | — | US | claimed |
| US-20040087637-A1 | 1-Aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH | 2004-05-06 | — | — | US | claimed |
| US-20030149018-A1 | 1-aryl- or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH | 2003-08-07 | — | — | US | claimed |
| US-6509357-B1 | Use there of for the therapeutic treatment of disorders relating to or affected by the 5-HT6 receptor. Various central nervous system disorders such as anxiety, depression, motor disorders, etc., are believed to involve a disturbance of the | WYETH | 2003-01-21 | — | — | US | claimed |
| US-20090239863-A1 | 1-ARYL-OR 1- ALKYLSULFONYLBENZAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH (US) | 2009-09-24 | — | — | US | disclosed |
| US-20090239863-A1 | 1-ARYL-OR 1- ALKYLSULFONYLBENZAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH (US) | 2009-09-24 | — | — | US | disclosed |
| US-7541358-B2 | 1-Substituted indoles, benzimidazoles additionally substituted with an amino ligand, e.g., 1-[(5-chlorothien-2-yl)sulfonyl]-5-[2-(piperidin-1-yl)ethoxy]-1H-indole; treating schizophrenia, depression, attention deficit disorder, Alzheimer's disease and Parkinson's disease | WYETH (US) | 2009-06-02 | — | — | US | disclosed |
| US-7541358-B2 | 1-Substituted indoles, benzimidazoles additionally substituted with an amino ligand, e.g., 1-[(5-chlorothien-2-yl)sulfonyl]-5-[2-(piperidin-1-yl)ethoxy]-1H-indole; treating schizophrenia, depression, attention deficit disorder, Alzheimer's disease and Parkinson's disease | WYETH (US) | 2009-06-02 | — | — | US | disclosed |
| US-20080027055-A1 | 1-Aryl-or 1-alkylsulfonnylbenzazole derivatives as 5-hydoxytryptamine-6 ligands | WYETH (US) | 2008-01-31 | — | — | US | disclosed |
| US-20080027055-A1 | 1-Aryl-or 1-alkylsulfonnylbenzazole derivatives as 5-hydoxytryptamine-6 ligands | WYETH (US) | 2008-01-31 | — | — | US | disclosed |
| US-7271180-B2 | 1-Aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2007-09-18 | — | — | US | disclosed |
| US-6919354-B2 | 1-aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2005-07-19 | — | — | US | disclosed |
| US-20050009819-A1 | 1-Aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2005-01-13 | — | — | US | disclosed |
| US-20040092564-A1 | 1-Aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH | 2004-05-13 | — | — | US | disclosed |
| US-20040087637-A1 | 1-Aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH | 2004-05-06 | — | — | US | disclosed |
| US-6710069-B2 | FOR THERAPY OF CENTRAL NERVOUS SYSTEM DISORDERS | WYETH | 2004-03-23 | — | — | US | disclosed |
| US-20030149018-A1 | 1-aryl- or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH | 2003-08-07 | — | — | US | disclosed |
| US-6509357-B1 | Use there of for the therapeutic treatment of disorders relating to or affected by the 5-HT6 receptor. Various central nervous system disorders such as anxiety, depression, motor disorders, etc., are believed to involve a disturbance of the | WYETH | 2003-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239863-A1 | 1-ARYL-OR 1- ALKYLSULFONYLBENZAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | HTR6, HTR1B, HTR1A | HTR6 1/4885HRH3 193/4885KCNH2 835/4885 |
| US-20030149018-A1 | 1-aryl- or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands | HTR6, HTR1B, HTR1A | HTR6 1/4885HRH3 196/4885KCNH2 914/4885 |
| US-20040087637-A1 | 1-Aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands | HTR6, HTR1B, HTR1A | HTR6 1/4885HRH3 196/4885KCNH2 914/4885 |
| US-20080027055-A1 | 1-Aryl-or 1-alkylsulfonnylbenzazole derivatives as 5-hydoxytryptamine-6 ligands | HTR6, HTR1B, HTR3B | HTR6 1/4885HRH3 135/4885KCNH2 733/4885 |
| US-20040092564-A1 | 1-Aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands | HTR6, HTR1B, HTR1A | HTR6 1/4885HRH3 196/4885KCNH2 914/4885 |
| US-20050009819-A1 | 1-Aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands | HTR6, HTR1B, HTR1A | HTR6 1/4885HRH3 193/4885KCNH2 835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.